Karyopharm Therapeutics Capital Expenditures Over Time
| KPTI Stock | USD 0.74 0.01 0.99% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Karyopharm Therapeutics Performance and Karyopharm Therapeutics Correlation. Karyopharm |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Expenditures Analysis
Compare Karyopharm Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Capital Expenditures Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 34.9 K | 74 K | 202 K | 57 K | 279 K | 50 K | 47.5 K |
| DMAC | 103.5 K | 79.3 K | 63.4 K | 134.3 K | 31.3 K | 5.4 K | 6.9 K | 22 K | 50 K | 2 K | 47 K | 22 K | 81 K | 24 K | 22.8 K |
| VALN | 3.7 M | 8.1 M | 822 K | 3.3 M | 3.7 M | 2.6 M | 3.7 M | 4 M | 3.2 M | 10.9 M | 19.5 M | 93.2 M | 29.3 M | 14.3 M | 12.3 M |
| VANI | 196.1 K | 196.1 K | 196.1 K | 246 K | 560.4 K | 762 K | 490 K | 265 K | 163 K | 493 K | 150 K | 572 K | 338 K | 887 K | 469.6 K |
| DNLI | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 6.1 M | 2.9 M | 3.4 M | 17.9 M | 3.1 M | 8.5 M | 17.8 M | 12.9 M | 9.3 M |
| DNTH | 139 K | 139 K | 139 K | 139 K | 139 K | 139 K | 139 K | 2.2 M | 7.7 M | 3.1 M | 400 K | 33 K | 139 K | 110 K | 104.5 K |
| DOMH | 300 K | 4.9 K | 2.3 K | 2 M | 1 M | 2 K | 4 K | 0.0 | 36 K | 360 K | 1.5 M | 617 K | 1.8 M | 427 K | 709.8 K |
| VCEL | 400 K | 1 M | 273 K | 40 K | 829 K | 2.4 M | 1.4 M | 1.5 M | 2.7 M | 2.6 M | 2.6 M | 7.9 M | 7.6 M | 27.5 M | 28.9 M |
| VCNX | 793 K | 793 K | 793 K | 793 K | 793 K | 793 K | 793 K | 68 K | 235 K | 78 K | 290 K | 32 K | 99 K | 67 K | 63.6 K |
| VCYT | 276 K | 276 K | 1.5 M | 1.3 M | 2 M | 6.2 M | 4.2 M | 1.8 M | 1.9 M | 2.8 M | 2.8 M | 5.4 M | 8.5 M | 10 M | 10.5 M |
Karyopharm Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Capital Expenditures description
Capital Expenditures are funds used by Karyopharm Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Karyopharm Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.My Equities
My Current Equities and Potential Positions
| Karyopharm Therapeutics | KPTI |
| Classification | Cancer Fighters |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.7372
Check out Karyopharm Therapeutics Performance and Karyopharm Therapeutics Correlation. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Karyopharm Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.